Funded Startups in Burlingame
Burlingame, California has generated funding rounds across a broad range of stages and sectors, with the 38 entries here spanning May 2020 through Septembe…
Burlingame, California has generated funding rounds across a broad range of stages and sectors, with the 38 entries here spanning May 2020 through September 2025. Artificial intelligence accounts for the largest single-sector cluster — seven distinct AI companies appear, including Butlr (Series B, $33M, August 2024), Signos (Series B, $20M, October 2023), and Neurvona (Pre-Seed, $600K, August 2025) — while biotechnology contributes six entries, among them Inflammatix (Series E, $57M, September 2024) and Protillion Biosciences (Series A, $18M, December 2022).
The largest disclosed rounds include Eolian's $390M in July 2024, Lyra Health's $235M Series F in January 2022, and Proterra's $200M in October 2020. Late-stage activity has continued into 2025 — Aven's $110M Series E in September 2025 is the most recent large disclosed round — while the dataset also contains sub-$1M entries such as Psyched Services' $300K (February 2025) and Neurvona's $600K Pre-Seed (August 2025), reflecting activity at both ends of the funding spectrum.
Most recent rounds
38 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Burlingame startups?
Eolian tops the list with $390M in July 2024 (energy), followed by Lyra Health's $235M Series F in January 2022 and Proterra's $200M in October 2020. Aven's $110M Series E in September 2025 and Imply's $100M Series D in May 2022 are the next largest, with Neptune Medical's $97M Series D in August 2024 and Inflammatix's $57M Series E in September 2024 rounding out the top tier.
Which sectors have the most funding activity among Burlingame startups in this data?
Artificial intelligence leads with seven companies — Butlr, Signos, unitQ, Focal Systems, Beehive AI, Neurvona, and xAI. Biotechnology follows with six entries: Inflammatix, Corvus Pharmaceuticals, Tallac Therapeutics, Apexigen, Cala Health, and Protillion Biosciences. Administrative services accounts for five additional companies, anchored by Lyra Health's $235M Series F and including Share Creators, BarRaiser, ARES PRISM, and Tugboat Logic.
Has late-stage funding remained active in Burlingame through 2024 and 2025?
Three sizable late-stage closes appear within roughly 13 months: Neptune Medical's $97M Series D in August 2024, Inflammatix's $57M Series E in September 2024, and Aven's $110M Series E in September 2025. Series D and above account for six rounds across the full dataset, spanning sectors from data infrastructure (Imply) to medical devices (Neptune Medical) and apps (Aven, Color).
Are any companies in this dataset showing multiple funding rounds?
Butlr is the only company appearing twice: a $5M Series Unknown round in March 2023 followed by a $33M Series B in August 2024, representing a roughly 6× increase in round size between the two closes.
What does early-stage deal flow look like in Burlingame based on this data?
The smallest rounds include Neurvona's $600K Pre-Seed in August 2025 and Psyched Services' $300K in February 2025. Seed rounds appear four times — Instock ($3M, December 2023), Beehive AI ($5M, June 2023), BarRaiser ($4M, May 2022), and 247PRO ($2M, August 2022) — showing consistent early-stage activity across multiple years.
How are funding stages distributed across the 38 entries?
"Series Unknown" is the most common label, covering 11 entries, with one additional "Venture - Series Unknown" entry (ARES PRISM). Series B appears seven times, Seed four times, and both Series A and Series E three times each. Series D accounts for two rounds; Series C, Series F, Pre-Seed, Debt Financing, and Corporate Round each appear once, and two entries carry no stage label.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.